JP2022504181A5 - - Google Patents

Info

Publication number
JP2022504181A5
JP2022504181A5 JP2021518472A JP2021518472A JP2022504181A5 JP 2022504181 A5 JP2022504181 A5 JP 2022504181A5 JP 2021518472 A JP2021518472 A JP 2021518472A JP 2021518472 A JP2021518472 A JP 2021518472A JP 2022504181 A5 JP2022504181 A5 JP 2022504181A5
Authority
JP
Japan
Prior art keywords
scleroderma
systemic sclerosis
compound
composition
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021518472A
Other languages
English (en)
Japanese (ja)
Other versions
JP7265620B2 (ja
JP2022504181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/054576 external-priority patent/WO2020072824A1/en
Publication of JP2022504181A publication Critical patent/JP2022504181A/ja
Publication of JP2022504181A5 publication Critical patent/JP2022504181A5/ja
Priority to JP2023055658A priority Critical patent/JP2023082117A/ja
Application granted granted Critical
Publication of JP7265620B2 publication Critical patent/JP7265620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021518472A 2018-10-03 2019-10-03 強皮症の治療のための方法 Active JP7265620B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023055658A JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862740855P 2018-10-03 2018-10-03
US62/740,855 2018-10-03
PCT/US2019/054576 WO2020072824A1 (en) 2018-10-03 2019-10-03 Methods for the treatment of scleroderma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023055658A Division JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Publications (3)

Publication Number Publication Date
JP2022504181A JP2022504181A (ja) 2022-01-13
JP2022504181A5 true JP2022504181A5 (enExample) 2022-09-29
JP7265620B2 JP7265620B2 (ja) 2023-04-26

Family

ID=68290393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518472A Active JP7265620B2 (ja) 2018-10-03 2019-10-03 強皮症の治療のための方法
JP2023055658A Pending JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023055658A Pending JP2023082117A (ja) 2018-10-03 2023-03-30 強皮症の治療のための方法

Country Status (5)

Country Link
US (1) US20210386706A1 (enExample)
EP (1) EP3860590B1 (enExample)
JP (2) JP7265620B2 (enExample)
ES (1) ES2951870T3 (enExample)
WO (1) WO2020072824A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190113955A (ko) * 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh) * 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) * 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
MX2021008263A (es) * 2019-01-08 2021-10-13 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Similar Documents

Publication Publication Date Title
JP2023076465A5 (enExample)
JP3667381B2 (ja) 解熱鎮痛剤
JP5442178B2 (ja) ロキソプロフェン含有経口用組成物
US20230414519A1 (en) Rapidly infusing compositions with methotrexate and treatment methods
JP2008521784A5 (enExample)
JP2015512406A5 (enExample)
JP2022516662A5 (enExample)
JP2022545156A5 (enExample)
JP2021073257A5 (enExample)
CN111065384A (zh) 扑热息痛的口腔崩解膜组合物
JP2022511788A5 (enExample)
JP2013087061A (ja) 積層錠
JP3122748B2 (ja) イブプロフェン含有解熱鎮痛剤
ES2248850T3 (es) Formulaciones farmaceuticas que contienen sales de potasiom sodio y tris de oxaprozina.
JP2023531930A5 (enExample)
JP2016056195A (ja) ロキソプロフェン含有経口用組成物5
JP4614640B2 (ja) 解熱剤組成物
JP2021066751A (ja) 経口用医薬組成物
JP6018891B2 (ja) 解熱鎮痛組成物
KR20130086771A (ko) 새로운 조합의 구강내 속붕해 필름형성 조성물 및 pde5 저해제가 함유된 구강내 속붕해 필름제제
JP2024511091A5 (enExample)
JP5742352B2 (ja) 解熱鎮痛組成物
JP5303605B2 (ja) サリチル酸類含有経口組成物
JP4917255B2 (ja) サリチル酸類含有経口組成物
JP2022550458A5 (enExample)